Geode Capital Management
ALLO icon

Geode Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Geode Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Buy
7,049,328
+2,925,150
+71% +$6.42M ﹤0.01% 2329
2026
Q1 		$10.1M Buy
4,124,178
+191,268
+5% +$383K ﹤0.01% 2375
2025
Q4 		$5.39M Buy
3,932,910
+99,025
+3% +$131K ﹤0.01% 2726
2025
Q3 		$4.75M Buy
3,833,885
+39,058
+1% +$46.6K ﹤0.01% 2808
2025
Q2 		$4.29M Buy
3,794,827
+435,389
+13% +$579K ﹤0.01% 2806
2025
Q1 		$4.91M Buy
3,359,438
+126,820
+4% +$239K ﹤0.01% 2663
2024
Q4 		$6.89M Buy
3,232,618
+5,514
+0.2% +$13.6K ﹤0.01% 2573
2024
Q3 		$9.04M Buy
3,227,104
+407,070
+14% +$1.09M ﹤0.01% 2446
2024
Q2 		$6.57M Buy
2,820,034
+448,700
+19% +$1.32M ﹤0.01% 2580
2024
Q1 		$10.6M Buy
2,371,334
+36,139
+2% +$151K ﹤0.01% 2291
2023
Q4 		$7.5M Buy
2,335,195
+263,842
+13% +$748K ﹤0.01% 2487
2023
Q3 		$6.57M Buy
2,071,353
+243,571
+13% +$1.07M ﹤0.01% 2502
2023
Q2 		$9.08M Buy
1,827,782
+78,538
+4% +$425K ﹤0.01% 2340
2023
Q1 		$8.64M Buy
1,749,244
+42,784
+3% +$274K ﹤0.01% 2348
2022
Q4 		$10.7M Buy
1,706,460
+77,793
+5% +$720K ﹤0.01% 2222
2022
Q3 		$17.6M Buy
1,628,667
+160,061
+11% +$2.18M ﹤0.01% 1832
2022
Q2 		$16.7M Buy
1,468,606
+207,355
+16% +$1.84M ﹤0.01% 1879
2022
Q1 		$11.5M Sell
1,261,251
-117,652
-9% -$1.23M ﹤0.01% 2260
2021
Q4 		$20.6M Buy
1,378,903
+118,850
+9% +$2.1M ﹤0.01% 1946
2021
Q3 		$32.4M Buy
1,260,053
+31,972
+3% +$759K ﹤0.01% 1640
2021
Q2 		$32M Buy
1,228,081
+155,250
+14% +$4.43M ﹤0.01% 1665
2021
Q1 		$37.9M Buy
1,072,831
+83,925
+8% +$2.83M 0.01% 1447
2020
Q4 		$25M Buy
988,906
+46,980
+5% +$1.53M ﹤0.01% 1582
2020
Q3 		$35.5M Buy
941,926
+35,849
+4% +$1.35M 0.01% 1108
2020
Q2 		$38.8M Buy
906,077
+170,840
+23% +$6.18M 0.01% 1033
2020
Q1 		$14.3M Buy
735,237
+56,183
+8% +$1.34M ﹤0.01% 1514
2019
Q4 		$17.6M Buy
679,054
+25,869
+4% +$712K ﹤0.01% 1645
2019
Q3 		$17.8M Buy
653,185
+239,671
+58% +$6.83M ﹤0.01% 1562
2019
Q2 		$11.1M Buy
413,514
+102,625
+33% +$2.86M ﹤0.01% 1875
2019
Q1 		$8.99M Sell
310,889
-8,179
-3% -$237K ﹤0.01% 1971
2018
Q4 		$8.59M Buy
+319,068
New +$8.48M ﹤0.01% 1872

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management's ALLO Position: Q2 2026 in Review

Geode Capital Management increased its Allogene Therapeutics (ALLO) stake by 71% in Q2 2026, buying an estimated $6.42M and bringing the position to 7,049,328 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2329.

Geode Capital Management first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $38.8M in Q2 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Geode Capital Management held 7,049,328 shares of Allogene Therapeutics worth $14.7M as of Q2 2026.
  • Geode Capital Management bought 2,925,150 Allogene Therapeutics shares in Q2 2026, an estimated $6.42M.
  • Allogene Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2329 holding.
  • Geode Capital Management first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Geode Capital Management's Allogene Therapeutics position peaked at $38.8M in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.